Literature DB >> 26092829

Nonblood/urine biomarker of progression of kidney disease in diabetes mellitus.

Ramin Tolouian1, Aaron I Vinik2.   

Abstract

Entities:  

Keywords:  CKD progression; autonomic dysfunction; biomarkers; diabetic nephropathy

Mesh：

Year:  2015        PMID： 26092829      PMCID： PMC4491289          DOI： 10.2215/CJN.05640515

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN： 1555-9041            Impact factor:   8.237


× No keyword cloud information.
  22 in total

1.  The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis.

Authors:  Raelene E Maser; Braxton D Mitchell; Aaron I Vinik; Roy Freeman
Journal:  Diabetes Care       Date:  2003-06       Impact factor: 19.112

2.  Prediction of diabetic nephropathy: The need for a sweet biomarker.

Authors:  Ramin Tolouian; German T Hernandez
Journal:  J Nephropathol       Date:  2013-01-01

3.  Mechanisms of autonomic nervous system dysfunction in uremia.

Authors:  V M Campese; M S Romoff; D Levitan; K Lane; S G Massry
Journal:  Kidney Int       Date:  1981-08       Impact factor: 10.612

4.  Sudoscan, a noninvasive tool for detecting diabetic small fiber neuropathy and autonomic dysfunction.

Authors:  Carolina M Casellini; Henri K Parson; Margaret S Richardson; Marie L Nevoret; Aaron I Vinik
Journal:  Diabetes Technol Ther       Date:  2013-07-27       Impact factor: 6.118

5.  Renal afferent impulses, the posterior hypothalamus, and hypertension in rats with chronic renal failure.

Authors:  S Ye; B Ozgur; V M Campese
Journal:  Kidney Int       Date:  1997-03       Impact factor: 10.612

6.  Autonomic dysregulation in patients awaiting kidney transplantation.

Authors:  D K Hathaway; A K Cashion; E J Milstead; R P Winsett; P A Cowan; M N Wicks; A O Gaber
Journal:  Am J Kidney Dis       Date:  1998-08       Impact factor: 8.860

7.  Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.

Authors:  Rodica Pop-Busui; Gregory W Evans; Hertzel C Gerstein; Vivian Fonseca; Jerome L Fleg; Byron J Hoogwerf; Saul Genuth; Richard H Grimm; Marshall A Corson; Ronald Prineas
Journal:  Diabetes Care       Date:  2010-03-09       Impact factor: 19.112

8.  Effects of intensive glucose lowering in type 2 diabetes.

Authors:  Hertzel C Gerstein; Michael E Miller; Robert P Byington; David C Goff; J Thomas Bigger; John B Buse; William C Cushman; Saul Genuth; Faramarz Ismail-Beigi; Richard H Grimm; Jeffrey L Probstfield; Denise G Simons-Morton; William T Friedewald
Journal:  N Engl J Med       Date:  2008-06-06       Impact factor: 91.245

9.  How to find a prognostic biomarker for progressive diabetic nephropathy.

Authors:  Frank C Brosius; Subramaniam Pennathur
Journal:  Kidney Int       Date:  2013-06       Impact factor: 10.612

10.  Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial.

Authors:  S Yusuf; K Teo; C Anderson; J Pogue; L Dyal; I Copland; H Schumacher; G Dagenais; P Sleight
Journal:  Lancet       Date:  2008-08-29       Impact factor: 79.321
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.